Ivabradine Tablet, Film Coated
Product Images NDC 31722-053

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Ivabradine (NDC 31722-053). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

5mg-60s (5mg 60s)

5mg-60s (5mg 60s)
This is a description of Ivabradine Tablets 5mg by CAMBER. Each film-coated tablet contains 5 mg Ivabradine as hydrochloride for oral use. Follow recommended dosage instructions as per prescribing information. Store at 25°C, with excursions allowed between 15-30°C. Keep tablets in the original bottle with desiccant and oxygen scavengers. Keep out of reach of children. Contact U.S. Number: 1-866-495-1395. For more information, visit camberpharma.com. Manufactured for Camber Pharmaceuticals, Inc., Piscataway, NJ.*
FDA Label Image

7-5mg60 (7 5mg60)

7-5mg60 (7 5mg60)
This text provides detailed information about the medication "Ivabradine Tablets" by Camber Pharmaceuticals. It includes the drug's NDC code, dosage information, storage recommendations, contact details, and manufacturing information. The tablets contain 7.5 mg of ivabradine hydrochloride. Patients are advised to refer to the medication guide for more details. The medication is for oral use only and should be stored at controlled room temperature. The manufacturer is located in Piscataway, New Jersey.*
FDA Label Image

Camber (Camber)

FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
This is a statistical table presenting data on the percentage of the total population represented by different variables such as age, sex, race, cause of heart failure, weight quartile, baseline heart rate quartile, NYHA class, baseline LV ejection fraction quartile, baseline beta blocker use quartile, baseline aldosterone antagonist use, diabetes history, and hypertension history, among others. The table also shows the percentage breakdown of Ivabradine and Placebo groups within each variable category, along with hazard ratios and their 95% confidence intervals. The data seems to be related to a study or clinical trial analyzing the effects of Ivabradine in comparison to Placebo on different population groups with various characteristics.*
FDA Label Image

Ivabradinetabfig2 (Ivabradinetabfig2)

Ivabradinetabfig2 (Ivabradinetabfig2)
This is a list of medications, including strong CYP3A4 inhibitors like ketoconazole, moderate CYP3A4 inhibitors like diltiazem and verapamil, a CYP3A5 inducer, and other medications such as Sidenafil, Lackipine, Simvastatin, Lansoprazole, Omeprazole, and Warfarin. It's important to monitor drug interactions and consult with a healthcare professional before taking these medications together.*
FDA Label Image

Ivabradinetabfig3 (Ivabradinetabfig3)

Ivabradinetabfig3 (Ivabradinetabfig3)
The text provides data related to a clinical trial comparing the effects of a drug called Ivabradine with a placebo. The study includes the number of subjects at risk for each treatment group over a specific time frame measured in months following randomization. The information can be used to analyze the outcomes and progression of the trial in terms of the number of subjects remaining in the study at various time points.*
FDA Label Image

Ivabradinetabstructure (Ivabradinetabstructure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.